News | May 09, 2026
Lonza surges on biologics boom
Expands manufacturing push & locks in major growth deals
Expands manufacturing push & locks in major growth deals
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Pharma giant targets new standards of care
Collaboration integrates AJICAP™ technology with global manufacturing capabilities to streamline antibody-drug conjugate pipelines
Highlights Mirvetuximab-based regimen promise
This event will bring together global stakeholders to explore India’s growing capabilities in pharma and biopharma innovation, research, and manufacturing
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
